Allercet M Kid Tablets (Montelukast + Levocetirizine Dispersible)
Montelukast 4 mg, Levocetirizine dihydrochloride IP 2.5 mg Dispersible Tablets.
Indicated for treatment of allergic rhinitis.
Levocetirizine, the R-enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors. Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics.
Children aged 6 to 12 years: One tablet, once daily or as recommended by the physician.
Contraindicated in patients with known hypersensitivity to montelukast, levocetirizine, to other piperazine derivatives or to any of the excipients. Allercet M Kid tablet should not be administered in children with impaired renal function. Children 6 to 11 years of age with renal impairment.
Neuropsychiatric events have been reported in patients taking montelukast. Monitor closely and instruct patients to be alert for neuropsychiatric events.
Allercet-M KID may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma.